𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Underestimation of chronic hepatitis B virus infection in the United States of America

✍ Scribed by C. Cohen; A. A. Evans; W. T. London; J. Block; M. Conti; T. Block

Book ID
108886043
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
48 KB
Volume
0
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Hepatitis A Infection in Chronic Carrier
Hepatitis A Infection in Chronic Carriers of Hepatitis B Virus
✍ Reinhart Zachoval; Michael Roggendorf; Friedrich Deinhardt πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 441 KB πŸ‘ 2 views

By routine screening for serologic markers of hepatitis A and B in patients with acute hepatitis, 30 chronic carriers of hepatitis B virus with serologic evidence of acute hepatitis A and two patients with simultaneous acute infection with hepatitis A virus and hepatitis B virus were detected. For

Treatment of children with chronic hepat
Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options
✍ Maureen M. Jonas; Joan M. Block; Barbara A. Haber; Saul J. Karpen; W. Thomas Lon πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 437 KB πŸ‘ 2 views

Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited nu

Advances in the treatment of chronic hep
Advances in the treatment of chronic hepatitis B virus infection
✍ Adriana R. Marques; Stephen E. Straus πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 244 KB πŸ‘ 2 views

Recent advances in our understanding of the replicative mechanism of HBV, and the development of potent nucleoside analogues as clinically effective inhibitors of the HIV reverse transcriptase or herpesvirus polymerases has opened a new era in the treatment of chronic HBV infection. Single agent the